Skip to main content

Invega Hafyera FDA Approval History

Last updated by Judith Stewart, BPharm on Sep 2, 2021.

FDA Approved: Yes (First approved August 30, 2021)
Brand name: Invega Hafyera
Generic name: paliperidone palmitate
Dosage form: Extended-Release Injectable Suspension
Company: Janssen Pharmaceuticals, Inc.
Treatment for: Schizophrenia

Invega Hafyera (paliperidone palmitate) is a long-acting injectable atypical antipsychotic for the twice-yearly treatment of schizophrenia in adults.

Development timeline for Invega Hafyera

Sep  1, 2021Approval FDA Approves Invega Hafyera (paliperidone palmitate) for Twice-Yearly Treatment for Adults with Schizophrenia

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.